Qiangling Sun, Z. Gu, Lei Zhu, Xiaohua Yang, Weigang Zhao, Shubin Guan, W. Fang
{"title":"AB型胸腺瘤新细胞系的建立与鉴定","authors":"Qiangling Sun, Z. Gu, Lei Zhu, Xiaohua Yang, Weigang Zhao, Shubin Guan, W. Fang","doi":"10.21037/26058","DOIUrl":null,"url":null,"abstract":"Background: Thymoma has been recognized as the most prevalent tumor of anterior mediastinum. Nevertheless, due to the diverse classification of its subtypes and the absence of proper pre-clinical models, the therapeutic progress of thymoma has been hampered. Therefore, the present study reported the establishment and characterization of a novel human thymoma cell line, designated as T68, which may be useful for exploring the molecular and biological characteristics of thymoma. \n Methods: Thymoma cell line was derived from a male type AB patient aged 44 years. Furthermore, the morphology, growth rate and ultrastructure of this cell line, together with the expression of epithelial cell markers, were studied in this work. Morphology and immunohistochemical reactivity assays were conducted for the characterization of the established xenografts. Results: Thymoma cells grew and formed a monolayer in an adhering manner, with doubling time of 30 to 48 hrs. The ultrastructural analysis results revealed secretary vesicles and microfilaments, as well as the desmosomes and tight junctions. No reaction of the T68 cell line was observed to B-cell and T-cell lineage markers (e.g., TdT, CD5), while this cell line exhibited a more significant reaction to epithelial markers (e.g., CK8, CK18, CK19). The xenografted tumor was recognized as type AB thymoma. For the nude mice, the cell line exhibited tumorigenicity. In addition, the xenografts showed histologic characteristics that were comparable with the original tumor from which this cell line was derived. Conclusions: The established thymoma cell line and xenograft model proposed in this study is potential to be used for further multi-aspect studies of human thymoma biology and proposal of new treatment strategies.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/26058","citationCount":"0","resultStr":"{\"title\":\"Establishment and characterization of a novel cell line derived from type AB thymoma\",\"authors\":\"Qiangling Sun, Z. Gu, Lei Zhu, Xiaohua Yang, Weigang Zhao, Shubin Guan, W. Fang\",\"doi\":\"10.21037/26058\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Thymoma has been recognized as the most prevalent tumor of anterior mediastinum. Nevertheless, due to the diverse classification of its subtypes and the absence of proper pre-clinical models, the therapeutic progress of thymoma has been hampered. Therefore, the present study reported the establishment and characterization of a novel human thymoma cell line, designated as T68, which may be useful for exploring the molecular and biological characteristics of thymoma. \\n Methods: Thymoma cell line was derived from a male type AB patient aged 44 years. Furthermore, the morphology, growth rate and ultrastructure of this cell line, together with the expression of epithelial cell markers, were studied in this work. Morphology and immunohistochemical reactivity assays were conducted for the characterization of the established xenografts. Results: Thymoma cells grew and formed a monolayer in an adhering manner, with doubling time of 30 to 48 hrs. The ultrastructural analysis results revealed secretary vesicles and microfilaments, as well as the desmosomes and tight junctions. No reaction of the T68 cell line was observed to B-cell and T-cell lineage markers (e.g., TdT, CD5), while this cell line exhibited a more significant reaction to epithelial markers (e.g., CK8, CK18, CK19). The xenografted tumor was recognized as type AB thymoma. For the nude mice, the cell line exhibited tumorigenicity. In addition, the xenografts showed histologic characteristics that were comparable with the original tumor from which this cell line was derived. Conclusions: The established thymoma cell line and xenograft model proposed in this study is potential to be used for further multi-aspect studies of human thymoma biology and proposal of new treatment strategies.\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.21037/26058\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/26058\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/26058","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Establishment and characterization of a novel cell line derived from type AB thymoma
Background: Thymoma has been recognized as the most prevalent tumor of anterior mediastinum. Nevertheless, due to the diverse classification of its subtypes and the absence of proper pre-clinical models, the therapeutic progress of thymoma has been hampered. Therefore, the present study reported the establishment and characterization of a novel human thymoma cell line, designated as T68, which may be useful for exploring the molecular and biological characteristics of thymoma.
Methods: Thymoma cell line was derived from a male type AB patient aged 44 years. Furthermore, the morphology, growth rate and ultrastructure of this cell line, together with the expression of epithelial cell markers, were studied in this work. Morphology and immunohistochemical reactivity assays were conducted for the characterization of the established xenografts. Results: Thymoma cells grew and formed a monolayer in an adhering manner, with doubling time of 30 to 48 hrs. The ultrastructural analysis results revealed secretary vesicles and microfilaments, as well as the desmosomes and tight junctions. No reaction of the T68 cell line was observed to B-cell and T-cell lineage markers (e.g., TdT, CD5), while this cell line exhibited a more significant reaction to epithelial markers (e.g., CK8, CK18, CK19). The xenografted tumor was recognized as type AB thymoma. For the nude mice, the cell line exhibited tumorigenicity. In addition, the xenografts showed histologic characteristics that were comparable with the original tumor from which this cell line was derived. Conclusions: The established thymoma cell line and xenograft model proposed in this study is potential to be used for further multi-aspect studies of human thymoma biology and proposal of new treatment strategies.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.